BACKGROUND Nonstatin lipid-lowering therapy is adjunctive therapy for high-risk individuals on statins or mono-
we defined an eligibility period as the 1 year before the start of the quarter (Online Figure 1) . To be eligible for a calendar quarter, beneficiaries were required to meet the following criteria: 1) be $65 years of age at the start of the eligibility period; 2) have a history of CHD documented during the look-back period; and 3) have continuous "full coverage" for Medicare, be in the 5%
Medicare sample, and live in the United States for the entire eligibility period and calendar quarter under study. We defined the look-back period as the time between the start of the eligibility period through the date of the first nonstatin lipid-lowering medication fill in the calendar quarter under study or as the midpoint of the calendar quarter for beneficiaries who did not fill a nonstatin lipid-lowering medication.
Additionally, we excluded beneficiaries who died before the end of the calendar quarter under study. We used an algorithm based on International Classification of Diseases-Ninth Edition-Clinical Modification (ICD-9-CM) and current procedure terminology codes to define a history of CHD (Online Table 1 
RESULTS
The current analysis included 310,091 Medicare beneficiaries. In the first quarter of 2007, 53.1% of Bittner et al.
Nonstatin Lipid-Lowering Therapy in Medicare Table 1 . These differences were similar across the study period (Online Table 2 ). In both crude and age-, sex-, and race/ethnicity-adjusted models, the use of nonstatin lipid-lowering medication decreased over successive calendar years and was lower at older age and among African Americans, Asian Americans, and Hispanics, compared to whites ( Table 2) . Being male, having diabetes, receiving care from a cardiologist, taking statins, and taking more medications overall were associated with a higher RR of nonstatin Bittner et al. CHD ¼ coronary heart disease; CI ¼ confidence interval. 
